The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a bidding war over the drugmaker Metsera. Lilly said Thursday that ...

Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake (Reuters) -Peter Marks, the former top vaccine regulator at the U.S. Food ...

Oct 6 (Reuters) - Eli Lilly (LLY.N), opens new tab will invest more than $1 billion in India in the coming years to boost manufacturing and supply through local drugmakers, the company said on Monday, ...

Mounjaro and Zepbound have helped boost the company's market cap. New data indicate these drugs do more than just help patients lose weight, contributing to potentially lowering risks to hearts and ...

The company's multibillion-dollar investments in manufacturing in the U.S. are likely to be warmly welcomed by the Trump administration. Eli Lilly's management has already committed to taking action ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The pharmacy argued in its ...

Eli Lilly stock (NYSE: LLY) should be on your radar. Here’s why – it is presently trading within the support range ($688 – $761), price points from which it has previously bounced significantly. Over ...

President Donald Trump announced on Sept. 25 that the U.S. will impose a 100% tariff on branded or patented pharmaceutical products that enter the country starting Oct 1. But Eli Lilly, one of ...

While Eli Lilly is rethinking its biotech incubator plans in Europe, the Big Pharma has gone ahead and opened its San Diego site. The Gateway Labs are co-working spaces for researchers that also act ...

(Reuters) -Eli Lilly said on Thursday the U.S. Food and Drug Administration has approved its treatment for a form of advanced breast cancer in adult patients who have received prior therapy. The ...

Eli Lilly has won the second FDA approval for an oral selective estrogen receptor degrader (SERD). Like the first oral SERD, Lilly’s imlunestrant is only cleared to treat ER-positive, HER2-negative ...